Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GCase activator reduces α-synuclein in mouse, patient-derived models of PD

DISEASE CATEGORY: Neurology

INDICATION: Parkinson's disease (PD)

Northwestern University researchers, including Lysosomal Therapeutics Inc.

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE